#AstraZeneca Plc (AZN) - Prohost Biotech

AstraZeneca’s Imfinzi Product Has Been Approved in the EU as the First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

AstraZeneca'a Imfinzi AstraZeneca ( AZN ) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel) has been approved in the Europe...

P

Prohost Biotech

Mar 20, 2026

AstraZeneca Imfinzi Granted Priority Review and Breakthrough Therapy Designation in US for Patients with Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers

AstraZeneca Imfinzi Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit If approved, this will be the first...

P

Prohost Biotech

Jul 30, 2025

AstraZeneca's Product Gefurulimab Demonstrated Daily Living of Adults with Generalised Myasthenia Gravis in PREVAIL Phase III Trial

AstraZeneca's Product Gefurulimab Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity at week 26. Positive...

P

Prohost Biotech

Jul 24, 2025

AstraZeneca Plans to Invest $50 billion in America for Medicines Manufacturing and R&D Generated in the US

AstraZeneca in the NEWS Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company’s...

P

Prohost Biotech

Jul 22, 2025

Altimmune, AstraZeneca and Alnylam Pharmaceuticals

Altimmune Altimmune ( ALT ) stock soared last Friday after speculation of a takeover by three large companies. The speculation died today. Nevertheless, other news about this firm could be important...

P

Prohost Biotech

Mar 17, 2025

AstraZeneca: Imfinzi-based Regimen Demonstrated Statistically Significant and Clinically Meaningful Improvement in Event-free Survival in Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers

AstraZeneca AstraZeneca ( AZN ) has positive high-level results from the MATTERHORN Phase III trial, which showed perioperative treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with st...

P

Prohost Biotech

Mar 7, 2025

AstraZeneca and Daiichi Sankyo Enhertu: CHMP Recommends Approval In The EU For Patients With HER2-low or HER2-Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy

AstraZeneca and Daiichi Sankyo AstraZeneca ( AZN ) and Daiichi Sankyo’s ( DSKYF ) (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monotherapy for the treatment o...

P

Prohost Biotech

Mar 4, 2025

The U.S. FDA Approved Daiichi Sankyo and AstraZeneca’s Product ENHERTU® for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

AstraZeneca FDA Approval On January 27, 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca ( AZN ) product ENHERTU® (fam-trastuzumab deruxtecan-nxki) was approved in the U.S. for the treatment of adult...

P

Prohost Biotech

Jan 29, 2025

AstraZeneca Product Trugap+Abiraterone and Androgen Deprivation Therapy Improved Primary Endpoint of Radiographic PFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

AstraZeneca in the NEWS AstraZeneca ( AZN ) Phase III trial CAPItello-281, which combines Truqap (capivasertib), abiraterone, and androgen deprivation therapy ( ADT ), demonstrates statistically signi...

P

Prohost Biotech

Nov 27, 2024

AstraZeneca Strengthens its Cardiovascular Pipeline with Agreement for a Pre-Clinical Novel Lipid-Lowering Therapy

AstraZeneca Agreement with CSPC Pharmaceutical Group Yesterday, October 7, 2024, AstraZeneca ( AZN ) announced it entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd ( CSPC...

P

Prohost Biotech

Oct 8, 2024

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

AstaZeneca Fasenra Approval AstraZeneca ( AZN ) product Fasenra (bevacizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)...

P

Prohost Biotech

Sep 19, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

AstraZeneca Imfinzi + Imjudo Updated results from the HIMALAYA Phase III trial have demonstrated that AstraZeneca ( AZN ) Imfinzi (durvalumab) plus Imjudo (tremelimumab) showed a sustained clinically...

P

Prohost Biotech

Sep 17, 2024

1m

1

News & Comments

AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin and Paclitaxel followed by IMFINZI Monotherapy for Adults with Primary Advanced or Recurrent Endometrial Cancer

US FDA Approval for AstraZeneca's IMFINZI AstraZeneca (AZN): The trial results of the FDA newly approved combination products demonstrated a reduction in the risk of disease progression or death by 58...

P

Prohost Biotech

Jun 17, 2024

Yes, Compugen's Stock is Soaring, But Why?

Compugen's Soaring Stock Many recent events led to Compugen's ( CGEN ) soaring stock after a huge decline in its price. In spite of the tremendous stock decline, Prohost never doubted the fact that C...

P

Prohost Biotech

Jan 2, 2024

Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

Sanofi Commercial Control of Beyfortus Against RSV In the morning, we promised to tell our readers how AstraZeneca's ( AZN ) , Sobi, and Sanofi ( SNY ) simplified their contractual arrangements that e...

P

Prohost Biotech

Apr 12, 2023

Comprehensive Prohost Letter #448

Comprehensive Prohost Letter Issues Coronavirus Variant Omicron A lot has happened since the coronavirus variant Omicron was discovered in South Africa. After having been responsible for a severe plum...

P

Prohost Biotech

Dec 22, 2021

AstraZeneca Granted FDA EUA for Long Acting Antibody Evusheld for Pre-Exposure Prophylaxis of Covid-19

AstraZeneca Long Acting Antibody Granted FDA EUA for COVID-19 Prevention AstraZeneca ( AZN ) product Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody ( LAAB ) combination rec...

P

Prohost Biotech

Dec 9, 2021

Ionis Pharmaceuticals to Collaborate with AstraZeneca in Treating Transthyretin Amyloidosis with Ionis Product Eplontersen

Ionis Pharmaceuticals and AstraZeneca in Collaboration to Treat ATTR with Eplontersen Ionis Pharmaceuticals ( IONS ) announced entering into a strategic collaboration agreement with AstraZeneca ( AZN...

P

Prohost Biotech

Dec 8, 2021

AstraZeneca Saphnelo Approved in Japan for Adult Patients with SLE

AstraZeneca Saphnelo Approved by Japanese Ministry of Health, Labor and Welfare Developed by AstraZeneca ( AZN ) , Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce over...

P

Prohost Biotech

Sep 28, 2021

AstraZeneca: Big Step Towards Improving the Lives of SLE Patients and More on Cassava Sciences

Cassava Sciences There is no doubt in our minds that Cassava Sciences’ ( SAVA ) product simufilam will play a major role in the treatment of Alzheimer’s disease. We have no doubt that simufilam has im...

P

Prohost Biotech

Aug 2, 2021

1m

2